These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1314242)

  • 1. Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: a randomized clinical trial.
    Andersen T; Astrup A; Quaade F
    Int J Obes Relat Metab Disord; 1992 Jan; 16(1):35-40. PubMed ID: 1314242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors.
    Swinburn BA; Carmichael HE; Wilson MR
    Int J Obes Relat Metab Disord; 1996 Nov; 20(11):1033-40. PubMed ID: 8923161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up.
    O'Connor HT; Richman RM; Steinbeck KS; Caterson ID
    Int J Obes Relat Metab Disord; 1995 Mar; 19(3):181-9. PubMed ID: 7780494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks.
    Drent ML; Zelissen PM; Koppeschaar HP; Nieuwenhuyzen Kruseman AC; Lutterman JA; van der Veen EA
    Int J Obes Relat Metab Disord; 1995 May; 19(5):299-304. PubMed ID: 7647820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice.
    Breum L; Pedersen JK; Ahlstrøm F; Frimodt-Møller J
    Int J Obes Relat Metab Disord; 1994 Feb; 18(2):99-103. PubMed ID: 8148931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Body weight evolution during dexfenfluramine treatment after initial weight control.
    Finer N
    Int J Obes Relat Metab Disord; 1992 Dec; 16 Suppl 3():S25-9. PubMed ID: 1338319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Horizontal or vertical banded gastroplasty after pretreatment with very-low-calorie formula diet: a randomized trial.
    Andersen T; Backer OG; Astrup A; Quaade F
    Int J Obes; 1987; 11(3):295-304. PubMed ID: 3312050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effect of dexfenfluramine on amino acid profiles and food selection in obese patients during weight loss.
    Breum L; Møller SE; Andersen T; Astrup A
    Int J Obes Relat Metab Disord; 1996 Feb; 20(2):147-53. PubMed ID: 8646251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tolerance and acceptability of dexfenfluramine in the long-term treatment of obesity in private practice. ESIM Group].
    Héraïef E
    Rev Med Suisse Romande; 1997 Jan; 117(1):19-24. PubMed ID: 9082531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged surveillance of dexfenfluramine in severe obesity.
    Mathus-Vliegen EM
    Neth J Med; 1993 Dec; 43(5-6):246-53. PubMed ID: 8107932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International trial of long-term dexfenfluramine in obesity.
    Guy-Grand B; Apfelbaum M; Crepaldi G; Gries A; Lefebvre P; Turner P
    Lancet; 1989 Nov; 2(8672):1142-5. PubMed ID: 2572857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects. A double-blind placebo-controlled study.
    Lafreniere F; Lambert J; Rasio E; Serri O
    Int J Obes Relat Metab Disord; 1993 Jan; 17(1):25-30. PubMed ID: 8383638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine.
    Pfohl M; Luft D; Blomberg I; Schmülling RM
    Int J Obes Relat Metab Disord; 1994 Jun; 18(6):391-5. PubMed ID: 8081430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug therapy after very-low-calorie diets.
    Finer N; Finer S; Naoumova RP
    Am J Clin Nutr; 1992 Jul; 56(1 Suppl):195S-198S. PubMed ID: 1615883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dexfenfluramine on resting metabolic rate and thermogenesis in premenopausal obese women during therapeutic weight reduction.
    Van Gaal LF; Vansant GA; Steijaert MC; De Leeuw IH
    Metabolism; 1995 Feb; 44(2 Suppl 2):42-5. PubMed ID: 7869937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
    Mathus-Vliegen EM;
    Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of dexfenfluramine on energy expenditure in obese patients on a very-low-calorie-diet.
    Recasens MA; Barenys M; Sola R; Blanch S; Masana L; Salas-Salvadó J
    Int J Obes Relat Metab Disord; 1995 Mar; 19(3):162-8. PubMed ID: 7780491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical observations on the treatment of obese patients with dexfenfluramine].
    Cairella M; Pisculli M; Petraroli AR; Riganelli S; Saracino A; Siani V
    Clin Ter; 1990 Jun; 133(5):289-97. PubMed ID: 2143712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexfenfluramine reduces cardiovascular risk factors.
    Bremer JM; Scott RS; Lintott CJ
    Int J Obes Relat Metab Disord; 1994 Apr; 18(4):199-205. PubMed ID: 8044193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.